ESRD end-stage renal disease, SNAC sodium N-(8-[2-hydroxybenzoyl] amino) caprylate Table 3 Pharmacokinetic endpoints for sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC) after the tenth dosing Parameters Renal function group (full analysis set) Normal (n = 24) Mild ( n = 12) Moderate ( n = 12) Severe ( n = 12) ESRD ( n = 11) AUC24,Day10 (nmol/C1h/L) 1028.8 (29.2) 1311.6 (31.5) 1335.9 (34.6) 1522.8 (31.8) 1471.4 (27.0) Cmax,Day10 (nmol/L) 971.4 (89.4) 1086.5 (99.0) 734.7 (70.4) 1074.4 (95.0) 936.3 (88.5) tmax,Day10 (h) 0.75 (0.33, 3.00) 0.58 (0.33, 2.50) 0.67 (0.33, 6.00) 0.67 (0.17, 1.00) 0.83 (0.17, 5.00) CLR (L/h) 0.06 (104.33) 0.08 (87.88) 0.09 (92.63) 0.04 (98.22) 0.01 (508.51) Data are geometric means (coefﬁcient of variation) except for tmax,Day10 where median (minimum, maximum) values are presented AUC24,Day10 area under the plasma concentration–time curve from time zero to 24 h after the tenth dose, CLR renal clearance, Cmax,Day10 maximum plasma concentration 0–24 h after the tenth dose, ESRD end-stage renal disease, tmax,Day10 time to reach Cmax,Day10, t/C145terminal half- life Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Renal Impairment 1577semaglutide that showed no clinically relevant effect on the pharmacokinetics of semaglutide when administered by subcutaneous injection in 56 subjects [ 15]. 